NCT03629756 - A Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Advanced Malignancies | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 24, 2018

Primary Completion Date

August 18, 2021

Study Completion Date

September 3, 2021

Conditions

Non-small Cell Lung CancerSquamous Cell Carcinoma of the Head and NeckBreast CancerColorectal CancerMelanomaBladder CancerOvarian CancerEndometrial CancerMerkel Cell CarcinomaGastroEsophageal CancerRenal Cell CarcinomaCastration-resistant Prostate Cancer

Interventions

DRUG

Etrumadenant

Etrumadenant is an A2aR and A2bR antagonist.

DRUG

Zimberelimab

Zimberelimab is a fully human anti-PD-1 monoclonal antibody.

Trial Locations (15)

2217

St. George Private Hospital, Kogarah

3144

Cabrini Health Limited, Malvern

4120

Gallipoli Medical Research Foundation, Greenslopes

28078

Carolina BioOncology Institute, Huntersville

29605

Prisma Health, Greenville

48073

QUEST Research Institute, Royal Oak

48109

University of Michigan, Ann Arbor

75702

Texas Oncology, P.A. - Tyler, Tyler

76104

Texas Oncology, P.A. - Fort Worth Cancer Center, Fort Worth

78240

Texas Oncology, P.A. - San Antonio Medical Center, San Antonio

80218

Rocky Mountain Cancer Centers (Midtown), Denver

85258

Scottsdale Healthcare Hospitals dba HonorHealth, Scottsdale

90024

University of California, Los Angeles, Los Angeles

90025

The Angeles Clinic and Research Institute, Los Angeles

99208

Medical Oncology Associates dba Summit Cancer Centers, Spokane